Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Oncocyte Corporation develops molecular diagnostic tests for transplant rejection and cancer therapy response. Its core products include blood-based assays for organ damage detection and oncology biomarkers, serving hospitals, transplant centers, and research institutions. The company leverages proprietary technology, strategic partnerships, and intellectual property to enable decentralized testing, aiming to improve patient outcomes, reduce healthcare costs, and foster innovation in personalized medicine.
This description was generated via AI from an annual report. Updated about 1 year ago.